Media

Latest News

PIQUR Announces First Human Topical Application of Bimiralisib

July 18, 2019

A Topical Dual-PI3K/mTOR inhibitor, in healthy volunteers followed by patients with the Rare Disease “Cutaneous T-Cell Lymphoma” in collaboration with the CHDR, LUMC, and SCARLETRED. Company Started Treatment of Healthy...

Read More

Dr. Melanie Rolli appointed as new Chief Executive Officer of PIQUR Therapeutics AG

May 7, 2019

The Board of Directors of PIQUR Therapeutics AG is pleased to announce the appointment of Dr. Melanie Rolli as Chief Executive Officer with immediate effect. Dr. Rolli joined PIQUR in...

Read More

Phase 2 Study – Bimiralisib in HNSCC recruiting now

March 29, 2019

Open-label, single arm, two-stage study, evaluating the efficacy and safety of bimiralisib in patients with recurrent or metastatic head and neck squamous cell carcinomas (HNSCC) harboring NOTCH1 loss of function...

Read More

PIQUR Renews Engagement with Tuberous Sclerosis Alliance Preclinical Consortium

November 30, 2018

SILVER SPRING, Md., Nov. 29, 2018 /PRNewswire/ — Today, the Tuberous Sclerosis Alliance (TS Alliance) announced a new staff member to drive its tuberous sclerosis complex (TSC) Preclinical Consortium.  Dean Aguiar, PhD, has joined...

Read More

Lasker Award for Advisory Board Member Michael N. Hall

September 9, 2017

Professor Michael N. Hall from the Biozentrum of the University of Basel receives the Lasker Basic Medical Research Award 2017 – one of the most distinguished honors in biomedical research....

Read More

PIQUR Receives EMA Orphan Drug Designation for PQR309 in Diffuse Large B-Cell Lymphoma

April 27, 2017

PIQUR Therapeutics AG, a Swiss clinical-stage pharmaceutical company, announced today that the European Medicines Agency (EMA) has granted orphan drug designation to PIQUR’s lead compound PQR309 for the treatment of...

Read More

PIQUR Strengthens Management Team with Key Hire, Melanie Rolli

March 21, 2017

Dr. Melanie Rolli joins PIQUR as new Chief Medical Officer PIQUR Therapeutics AG, a Swiss clinical-stage pharmaceutical company, announced today that it has strengthened its management team with the appointment...

Read More

PIQUR and PIERRE FABRE Announce Partnership in Dermato-Oncology

January 11, 2017

PIQUR Therapeutics AG, a Swiss clinical-stage pharmaceutical company, and Pierre Fabre, the second largest private French pharmaceutical group announced today that they have signed a collaboration agreement for the development...

Read More